55. Cost-Effectiveness of Osteoporosis Treatment

  1. Clifford J. Rosen MD
  1. Anna N.A. Tosteson

Published Online: 19 JUL 2013

DOI: 10.1002/9781118453926.ch55

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Eighth Edition

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Eighth Edition

How to Cite

Tosteson, A. N.A. (2013) Cost-Effectiveness of Osteoporosis Treatment, in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Eighth Edition (ed C. J. Rosen), John Wiley & Sons, Inc., Ames, USA. doi: 10.1002/9781118453926.ch55

Publication History

  1. Published Online: 19 JUL 2013

ISBN Information

Print ISBN: 9781118453889

Online ISBN: 9781118453926

SEARCH

Keywords:

  • incremental cost-effectiveness ratio (ICER);
  • osteoporosis treatment

Summary

This chapter describes the methodology of cost-effectiveness analysis. It discusses the recent developments in the cost-effectiveness of osteoporosis, and highlights the key findings. The incremental cost-effectiveness ratio (ICER), which estimates expected cost per unit of health gained, is the primary outcome measure used to characterize value in cost-effectiveness studies. The human capital approach, which values productivity changes based on lost earnings, has been applied to assess the cost of fractures in some U.S. cost-of-illness studies, but to date such costs have not been included in cost-effectiveness analyses of osteoporosis treatment. Fracture risk, treatment cost, the impact that fractures have on health-related quality of life, treatment persistence, and the durability of treatment all influence the value of osteoporosis treatment. Risk assessment tools for predicting 10-year fracture risk, provide a tool for efficiently targeting therapy to those individuals who stand to benefit most from osteoporosis treatment.